PO.TB10.06 · 肿瘤生物学

利用多重免疫荧光对肿瘤微环境进行空间分析的标准化泛癌框架

A standardized pan-cancer framework for spatial profiling of the tumor microenvironment using multiplex immunofluorescence

编号 792 展板 4 时间 4/19 02:00–05:00 区域 Section 32 主讲 Sidney van der Zande, BS;MS
分会场 Spatial Protein Profiling and Multi-Modal Mapping of Tumor and Circulating Ecosystems
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Sidney van der Zande1, Outi H. J. Hasu1, Zhiying He1, Katja E. Välimäki1, Tuomas Mirtti2, Antti S. Rannikko3, Heini J. Lassus4, Ari P. Ristimaki2, Pia Osterlund5, Tero A. Aittokallio1, Lassi Paavolainen1, Mikko J. Loukovaara4, Olli P. Kallioniemi1, Ralf C. Bützow4, Teijo S. Pellinen1

1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland,2Department of Pathology, Helsinki University Hospital, Helsinki, Finland,3Department of Urology, University of Helsinki, Helsinki, Finland,4Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland,5Faculty of Medicine and Health Technology, Tampere University Hospital, Tampere, Finland

摘要 Abstract

中文摘要
越来越多的研究表明,TME中细胞的空间布局和相互作用在决定患者预后和治疗反应方面起着关键作用。虽然人们已投入大量精力对单个癌症进行分析,但染色方法和分析流程的差异使得在泛癌背景下研究空间TME模式愈发困难。为解决这一问题,我们开发了标准化的多重免疫荧光(mIF)染色方案和计算流程,以分析来自子宫内膜癌、卵巢癌、乳腺癌、前列腺癌和结直肠癌组织微阵列的TME结构。我们的mIF面板包含多达50个蛋白靶点,捕获主要的免疫和基质群体、上皮状态以及干性标志物,使我们能够非常详细地分析TME。为实现高置信度的细胞分类,我们将经典阈值法与基于像素的模型和无监督聚类相结合,以生成共识细胞类型注释。我们的分析表明,基于像素和无监督聚类的方法通过增强对模糊信号的分离并提高可重复性,优于阈值法。纳入细胞形状参数进一步增强了对形态学上不同群体(如成纤维细胞和巨噬细胞)的识别。我们首先将该框架应用于一个由子宫内膜癌和卵巢癌组成的妇科发现集(n>1600例患者,多灶取样)。初步分析表明,均源自苗勒上皮的子宫内膜癌和子宫内膜样卵巢癌具有相似的免疫和基质谱,而卵巢透明细胞癌则显示出不同的TME组成。此外,B细胞比例降低和去分化上皮细胞比例增加均与子宫内膜癌复发密切相关(采用FDR校正的双侧t检验;两者p<0.001)。子宫内膜样卵巢癌在这些特征上显示出相似趋势,但未发现与复发有统计学显著的关联(p=0.453和p=0.055,顺序相同)。在卵巢透明细胞癌中,B细胞比例和去分化上皮细胞均未显示出与复发的任何关联(分别为p=0.339和p=0.339)。这些发现提示,癌症的起源细胞对TME组成的影响可能比疾病的解剖部位更强。总之,我们的工作将建立一个协调统一的泛癌mIF框架,并揭示具有临床相关性的保守TME特征。这些标准化工具能够实现跨癌症比较,提高空间生物标志物的可解释性,并可能指导广泛适用的治疗策略的开发。
查看英文原文 English abstract
A growing number of studies have shown the key role of the spatial layout and interactions between cells in the TME in determining patient prognosis and therapy response. While substantial effort has been invested in profiling individual cancers, differences in staining methods and analysis pipelines make it increasingly difficult to study spatial TME patterns in a pan-cancer setting. To address this issue, we developed standardized multiplex immunofluorescence (mIF) staining protocols and computational pipelines to profile TME architecture across tissue microarrays from endometrial, ovarian, breast, prostate, and colorectal carcinomas. Our mIF panels include up to 50 protein targets capturing major immune and stromal populations, epithelial states, and markers of stemness, allowing us to profile the TME in great detail. To achieve high-confidence cell classification, we integrated classical thresholding with pixel-based models and unsupervised clustering to produce a consensus cell-type annotation. Our analyses show that pixel-based and unsupervised clustering methods outperform thresholding by enhanced separation of ambiguous signal and improving reproducibility. Incorporating cellular shape parameters further enhanced the identification of morphologically distinct populations such as fibroblasts and macrophages. We first applied this framework to a gynecological discovery set comprising endometrial and ovarian carcinomas (n > 1600 patients, multifocal sampling). Preliminary analyses indicate that endometrial and endometrioid ovarian carcinomas, both derived from Müllerian epithelium, share similar immune and stromal profiles, whereas ovarian clear cell carcinoma shows a distinct TME composition. In addition, reduced fractions of B cells and increased fractions of dedifferentiated epithelial cells were both strongly associated with recurrence in endometrial carcinoma (two-sided t-test with FDR; both p < 0.001). Endometrioid ovarian carcinoma showed similar trends for these features, but no statistically significant associations with recurrence were found (p = 0.453 and p = 0.055, same order). Neither B-cell fraction nor dedifferentiated epithelial cells showed any association with recurrence in ovarian clear cell carcinoma (p = 0.339 and p = 0.339, respectively). These findings suggest that the cancer cell of origin may exert a stronger influence on TME composition than the anatomical site of disease. Together, our work will establish a harmonized pan-cancer mIF framework and reveal conserved TME features with clinical relevance. These standardized tools enable cross-cancer comparisons, improve the interpretability of spatial biomarkers, and may guide the development of broadly applicable therapeutic strategies.
利益披露 Disclosure
S. van der Zande, None.. O. H. J. Hasu, None.. Z. He, None.. K. E. Välimäki, None.. T. Mirtti, None.. A. S. Rannikko, None.. H. J. Lassus, None.. A. P. Ristimaki, None.. P. Osterlund, None.. T. A. Aittokallio, None.. L. Paavolainen, None.. M. J. Loukovaara, None. O. P. Kallioniemi, Sartar Therapeutics g., Board of Directors, non-salaried role). Knut and Alice Wallenberg Foundation Scientific Advisor. Novo Nordisk Foundation Scientific Advisor. R. C. Bützow, None.. T. S. Pellinen, None.

← 返回 AACR 2026 检索